Appendix 1: Acceptable intakes established for N-nitrosamines

Opinion/decision on a Paediatric investigation plan (PIP): Finasteride,tadalafil, decision type: , therapeutic area: , PIP number: P/0461/2022

Opinion/decision on a Paediatric investigation plan (PIP): Rosuvastatin (calcium),Telmisartan, decision type: , therapeutic area: , PIP number: P/0460/2022

Opinion/decision on a Paediatric investigation plan (PIP): Derivative of (3S,3'S,3a'S,10a'S)-3'-phenyl-3',3a',10',10a'-tetrahydro-1'H-spiro[indoline-3,2'- pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazol]-2-one, decision type: , therapeutic area: , PIP number: P/0459/2022

Responses to list of issues - GFR slope as a Surrogate Endpoint in RCT for CKD

EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep

Conversations on Cancer presents “Living with Metastatic Breast Cancer”, Online, 15:30 - 17:00 Amsterdam time (CEST), from 19/10/2023 to 19/10/2023

Registration guide - Union Product Database (UPD) for veterinary medicinal products

Human medicines European public assessment report (EPAR): Zavicefta, ceftazidime,avibactam, Pneumonia, Bacterial;Soft Tissue Infections;Pneumonia;Urinary Tract Infections;Gram-Negative Bacterial Infections, Date of authorisation: 23/06/2016, Revision: 15, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Lidocaine (hydrochloride monohydrate), decision type: , therapeutic area: , PIP number: P/0419/2022